Product Document Searching Made Easy by 2D Code! | TCI Chemistry News June 2026 | [TCIPracticalExample] Oxidation Reaction of Heterocycles Using... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
CAS RN: 138844-81-2 | Product Number: S0877
Sodium Ibandronate
Purity: >90.0%(T)
- Ibandronic Acid Sodium Salt
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | S0877 |
Purity / Analysis Method
|
>90.0%(T) |
| Molecular Formula / Molecular Weight | C__9H__2__2NNaO__7P__2 = 341.21 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 138844-81-2 |
Related CAS RN
|
114084-78-5 |
| Reaxys Registry Number | 14511791 |
| PubChem Substance ID | 160871235 |
| Merck Index (14) | 4873 |
| MDL Number | MFCD07197214 |
| Appearance | White to Almost white powder to crystal |
| Purity(Neutralization titration) | min. 90.0 % |
| Drying loss | max. 10.0 % |
| Solubility in water | Soluble |
| RTECS# | SZ8563300 |
| H.S.code* | 2931.49-000 |
References
- Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
- Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
- J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, M. J. Rogers, J. Pharmacol. Exp. Ther. 2001, 296, 235.
- Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
References
- 1)Anti-bone resorption
- a)J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, M. J. Rogers., J. Pharmacol. Exp. Ther. 2001, 296, 235.
- b)E. Hiroi-Furuya, T. Kameda, K. Hiura, H. Mano, K. Miyazawa, Y. Nakamaru, M. Watanabe-Mano, N. Okuda, J. Shimada, Y. Yamamoto, Y. Hakeda, M. Kumegawa, Calcif. Tissue Int. 1999, 64, 219.

- 2)In vitro anti-tumor effects and its in vivo role
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.